Gilead pencils in potential buyout of Pionyr Immunotherapeutics

23 Jun 2020

Pionyr's "promising, novel biology" could represent a major increase in Gileads's cancer pipeline.

Gilead Sciences has agreed to pay $275 million for a 49.9% share in Pionyr Immunotherapeutics, a privately held company developing first-in-class cancer immunotherapies, with the exclusive option to purchase the remainder of Pionyr.

Gilead pencils in potential buyout of Pionyr Immunotherapeutics

Whether or not Gilead chooses to buy the remaining shares may well rest upon the outcomes of the Phase Ib studies for PY314 and PY159. If they decide to go ahead, the remaining shares will cost then a further $315 million and up to $1.15 billion in potential future milestone payments.

In addition, Gilead will provide Pionyr with additional funding for the PY314 and PY159 clinical programs, as well as ongoing R&D programs.

Pionyr’s Myeloid Tuning therapies have the potential to treat patients who currently do not benefit from checkpoint inhibitor therapies. PY314 and PY159 have demonstrated preclinical efficacy, suggesting potential in solid tumors in combination with established anti-PD(L)-1 agents. Pionyr plans to file investigational new drug (IND) applications with the FDA for both PY314 and PY159 in the third quarter of this year.

“This agreement underscores the value of our myeloid tuning platform and the potential of our pipeline of antibody therapeutics designed to turbocharge the immune system within the tumor microenvironment,” said Steven P. James, President and CEO, Pionyr.

“PY314 and PY159 are first-in-class antibodies designed to remove or reprogram, respectively, the immune suppressive cells in the tumor microenvironment and thereby enhance anti-tumor immunity. We are grateful that Gilead has acknowledged the promise of this transformational approach to potentially benefit patients across a range of solid tumors.”

Read More

Related categories

Related tags

Market News

Related news

SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment

SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment

7 Jul 2020

The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.

Read more 
Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail

Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail

7 Jul 2020

The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.

Read more 
Croda bolsters position in life sciences with the acquisition of Avanti Polar Lipids

Croda bolsters position in life sciences with the acquisition of Avanti Polar Lipids

6 Jul 2020

The transaction will more than double Croda’s R&D capability in drug delivery.

Read more 
Rentschler Biopharma and Vetter team up to simplify processes

Rentschler Biopharma and Vetter team up to simplify processes

6 Jul 2020

Companies agree that the key to tackling drug development complexity is collaboration.

Read more 
Cambrex increases flexible manufacturing capacity at Karlskoga, Sweden facility

Cambrex increases flexible manufacturing capacity at Karlskoga, Sweden facility

6 Jul 2020

An investment of $3.6 million will cover the installation of a new production line to keep pace with continued growth in commercial-scale API manufacturing.

Read more 
iNova Pharmaceuticals announces the launch of iPitch 2020

iNova Pharmaceuticals announces the launch of iPitch 2020

3 Jul 2020

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.

Read more 
Ajinomoto introduces fast track platform for drug product manufacturing

Ajinomoto introduces fast track platform for drug product manufacturing

30 Jun 2020

AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.

Read more 
CPhI Worldwide to transform into Festival of Pharma digital experience

CPhI Worldwide to transform into Festival of Pharma digital experience

30 Jun 2020

The 10-day event will feature an interactive digital marketplace for sourcing products and services, enhanced matchmaking for connecting with new and existing partners, and world-renowned speakers.

Read more 
Catalent expands beauty and plant-based consumer health softgel capabilities

Catalent expands beauty and plant-based consumer health softgel capabilities

30 Jun 2020

Two company sites - one in Canada, the other in Brazil - receive new softgel encapsulation lines to service local customer demand.

Read more 
Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

29 Jun 2020

The company agrees to provide CEPI with 100 million glass vials, which can store 20 doses per vial (2 billion doses in total).

Read more